Navigation Links
WellSpring Pharmaceutical Corp. Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category
Date:4/21/2009

SARASOTA, Fla., April 21 /PRNewswire/ -- WellSpring Pharmaceutical Corporation announced earlier today that Emetrol (R), its liquid anti-nausea brand is now the leading product in its category. Based on trailing 52 weeks sales (ending 1/14/09) Emetrol(R) garnered 51.7 % of the brand category displacing all others including private label. The most recent IRI reports indicate that Emetrol (R) sales are up 24% over last year reflecting the fact that it is recommended by name by OB/GYN's, Pediatricians and Pharmacists. Over 90% of OB/GYN's interviewed indicate that they would most likely use Emetrol(R) as first line therapy in treating mild to moderate nausea.

For over 60 years, Emetrol(R) has provided consumers with reliable relief from nausea and vomiting. Emetrol (R) is popular with more and more consumers including women between the ages of 25 and 34 who seek Emetrol(R) due to their doctor or pharmacist's recommendation. Emetrol(R) is specifically recommended because it is safe, effective, and gives fast relief from nausea and vomiting due to upset stomach, flu, and food indiscretions. WellSpring has rolled out a national advertising campaign targeting this population segment. And the National Association of Pediatric Nurse Practitioners (NAPNAP) has selected Emetrol(R) for editorial content in their upcoming issue which reaches 3.5 million women ages 25-48.

WellSpring's President and CEO, Dr. Robert A. Vukovich commented on this announcement: "The Emetrol(R) brand is an important one for our company as we have seen remarkable growth in its sales over this past year. The fact that we are recommended by OB/GYN physicians for their patients experiencing nausea associated with pregnancy and by Pediatricians for children under their care, has proven to be one of the most important attributes of the brand. Containing a unique combination of phosphorylated carbohydrates Emetrol (R) is considered by these physicians as safe and effective for treating mild to moderate nausea. We will continue to invest heavily in the brand with a new national advertising campaign."

WellSpring Pharmaceutical Corporation is a closely held pharmaceutical company marketing both prescription and non-prescription consumer drug brands. The firm has headquarters in Sarasota, Florida and operates a state-of-the-art GMP compliant manufacturing facility in Canada.

    Contacts:

    Wendy Shusko, COO 941-312-4727
    Wayne Miller, VP Sales 941-312-4727

    WellSpring Pharmaceutical Corporation
    5911 North Honore Ave., Ste 211
    Sarasota, Fl  34243

Emetrol Website: www.emetrol.com


'/>"/>
SOURCE WellSpring Pharmaceutical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer
2. WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
3. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
4. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders
5. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
6. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
7. Strativa Pharmaceuticals Provides Product Pipeline Update
8. Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer
9. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
10. Sun Pharmaceutical Extends Tender Offer for Taro
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of ... Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities ... before the big event. The invitation-only gifting suite, held this year at the W ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... NC (PRWEB) , ... February 12, 2016 , ... AssureVest ... surrounding areas, is initiating a charity drive that will raise funds earmarked to purchase ... John C. Tayloe Elementary School. , “My school is in a low-income area and ...
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to bring patients ... office. Beginning in January, Miami Dental Specialists will offer the non-metal implants as a ... office to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
(Date:2/11/2016)... -- - Cardiac Marker Diagnostic Testing ... Cancer Therapy. - European Point of Care Diagnostic ... - Key Diagnostic Testing Markets. - Molecular Diagnostics ... Testing. - Molecular Diagnostics in Infectious Disease Testing. ... Products World Markets. - Point of Care Diagnostic ...
(Date:2/11/2016)... INC. (NasdaqCM: PDEX) today announced financial results for its fiscal ... filed its Quarterly Report on Form 10-Q for the second ... Commission today. --> --> ... --> Net sales for the three months ended ... million from $2.8 million for the three months ended December ...
Breaking Medicine Technology: